Pfizer, through its wholly owned subsidiary Eclipse Acquisition, has completed the acquisition of biopharmaceutical company Icagen.
As per the agreement, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6 in cash, without interest and less any applicable withholding and transfer taxes.
Icagen is now part of Pfizer’s worldwide R&D organisation, and will be integrated into Neusentis, Pfizer’s research unit.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Pharmaceutical Technology Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!
Nominate Now
